ID   NCI-ADR-RES
AC   CVCL_1452
AS   CVCL_0414; CVCL_3942
SY   NCI/ADR-RES; NCI.ADR.RES; NCIADR.RES; NCI/ADRRES; NCIADRRES; ADR-RES; MCF-7/ADR; MCF-7/ADR-RES; MCF-7/AdrR; MCF-7/Adr; MCF-7/adr; MCF-7ADR; MCF7-ADR; MCF7ADR; OVCAR-8/ADR; OVCAR8/ADR
DR   BTO; BTO:0004181
DR   MCCL; MCC:0000310
DR   ArrayExpress; E-MTAB-783
DR   BioGRID_ORCS_Cell_line; 390
DR   BioSample; SAMN03151880
DR   BioSample; SAMN03151881
DR   cancercelllines; CVCL_1452
DR   Cell_Model_Passport; SIDM00089
DR   ChEMBL-Cells; CHEMBL3308057
DR   ChEMBL-Targets; CHEMBL613829
DR   Cosmic; 687498
DR   Cosmic; 897420
DR   Cosmic; 905987
DR   Cosmic; 974233
DR   Cosmic; 1044218
DR   Cosmic; 1092617
DR   Cosmic; 1312358
DR   Cosmic; 1998459
DR   GEO; GSM2099
DR   GEO; GSM50197
DR   GEO; GSM50260
DR   GEO; GSM743473
DR   GEO; GSM750832
DR   GEO; GSM799367
DR   GEO; GSM799430
DR   GEO; GSM839041
DR   GEO; GSM847073
DR   GEO; GSM844614
DR   GEO; GSM844615
DR   GEO; GSM1153433
DR   GEO; GSM1181271
DR   GEO; GSM1181300
DR   GEO; GSM2124672
DR   IARC_TP53; 21533
DR   NCI-DTP; NCI/ADRRES
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   Progenetix; CVCL_1452
DR   PubChem_Cell_line; CVCL_1452
DR   SKY/M-FISH/CGH; 2897
DR   Wikidata; Q54907717
RX   DOI=10.4172/2157-7145.S2-005;
RX   PubMed=9625176;
RX   PubMed=10700174;
RX   PubMed=11416159;
RX   PubMed=15748285;
RX   PubMed=16504380;
RX   PubMed=17088437;
RX   PubMed=18304946;
RX   PubMed=19372543;
RX   PubMed=20143388;
RX   PubMed=21116879;
RX   PubMed=22068913;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22628656;
RX   PubMed=23933261;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=27377824;
RX   PubMed=27807467;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://dtp.cancer.gov/discovery_development/nci-60/nci-adrres.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=28
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7.
CC   Part of: NCI-60 cancer cell line panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00234.
CC   Population: Caucasian.
CC   Doubling time: 34 hours (NCI-DTP=NCI/ADRRES).
CC   HLA typing: A*01:01:01,25:01; B*57:01:01; C*06:02; DPB1*02:01:02,13:01; DQB1*03:03:02,06:02; DRB1*07:01,15:01:01 (PubMed=15748285).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
ST   Source(s): DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=19372543
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 13
ST   D18S51: 14
ST   D19S433: 14,16
ST   D21S11: 28
ST   D2S1338: 19,23
ST   D3S1358: 18
ST   D5S818: 12
ST   D7S820: 12
ST   D8S1179: 10
ST   FGA: 20
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1629 ! OVCAR-8
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 39
//
RX   DOI=10.4172/2157-7145.S2-005;
RA   Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.,
RA   Hart R.P., Furtado M.R.;
RT   "STR profiling of human cell lines: challenges and possible solutions
RT   to the growing problem.";
RL   J. Forensic Res. 2 Suppl. 2:5-5(2011).
//
RX   PubMed=9625176; DOI=10.1093/jnci/90.11.862;
RA   Scudiero D.A., Monks A., Sausville E.A.;
RT   "Cell line designation change: multidrug-resistant cell line in the
RT   NCI anticancer screen.";
RL   J. Natl. Cancer Inst. 90:862-862(1998).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=16504380; DOI=10.1016/j.canlet.2006.01.013;
RA   Liscovitch M., Ravid D.;
RT   "A case study in misidentification of cancer cell lines: MCF-7/AdrR
RT   cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human
RT   ovarian carcinoma cells.";
RL   Cancer Lett. 245:350-352(2007).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=18304946; DOI=10.1093/nar/gkn089;
RA   Demichelis F., Greulich H., Macoska J.A., Beroukhim R., Sellers W.R.,
RA   Garraway L.A., Rubin M.A.;
RT   "SNP panel identification assay (SPIA): a genetic-based assay for the
RT   identification of cell lines.";
RL   Nucleic Acids Res. 36:2446-2456(2008).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=21116879; DOI=10.1007/s12032-010-9747-1;
RA   Ke W.-F., Yu P., Wang J.-F., Wang R.-T., Guo C.-Y., Zhou L., Li C.-C.,
RA   Li K.;
RT   "MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7
RT   breast cancer cells: a loss for breast cancer multidrug-resistant
RT   research.";
RL   Med. Oncol. 28:S135-S141(2011).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//